Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

SLC19A1 transports immunoreactive cyclic dinucleotides.

Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH.

Nature. 2019 Sep;573(7774):434-438. doi: 10.1038/s41586-019-1553-0. Epub 2019 Sep 11.

PMID:
31511694
2.

Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A.

Nature. 2018 Jul;559(7715):E13. doi: 10.1038/s41586-018-0227-7.

PMID:
29899441
3.

Enhancer connectome in primary human cells identifies target genes of disease-associated DNA elements.

Mumbach MR, Satpathy AT, Boyle EA, Dai C, Gowen BG, Cho SW, Nguyen ML, Rubin AJ, Granja JM, Kazane KR, Wei Y, Nguyen T, Greenside PG, Corces MR, Tycko J, Simeonov DR, Suliman N, Li R, Xu J, Flynn RA, Kundaje A, Khavari PA, Marson A, Corn JE, Quertermous T, Greenleaf WJ, Chang HY.

Nat Genet. 2017 Nov;49(11):1602-1612. doi: 10.1038/ng.3963. Epub 2017 Sep 25.

4.

Discovery of stimulation-responsive immune enhancers with CRISPR activation.

Simeonov DR, Gowen BG, Boontanrart M, Roth TL, Gagnon JD, Mumbach MR, Satpathy AT, Lee Y, Bray NL, Chan AY, Lituiev DS, Nguyen ML, Gate RE, Subramaniam M, Li Z, Woo JM, Mitros T, Ray GJ, Curie GL, Naddaf N, Chu JS, Ma H, Boyer E, Van Gool F, Huang H, Liu R, Tobin VR, Schumann K, Daly MJ, Farh KK, Ansel KM, Ye CJ, Greenleaf WJ, Anderson MS, Bluestone JA, Chang HY, Corn JE, Marson A.

Nature. 2017 Sep 7;549(7670):111-115. doi: 10.1038/nature23875. Epub 2017 Aug 30. Erratum in: Nature. 2018 Jul;559(7715):E13.

5.

Cornerstones of CRISPR-Cas in drug discovery and therapy.

Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE.

Nat Rev Drug Discov. 2017 Feb;16(2):89-100. doi: 10.1038/nrd.2016.238. Epub 2016 Dec 23. Review.

6.

A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells.

Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, Hesser CR, Dietzen PA, Russell T, Iannello A, Coscoy L, Sentman CL, Carette JE, Muljo SA, Raulet DH.

Elife. 2015 Nov 13;4. pii: e08474. doi: 10.7554/eLife.08474.

7.

Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH.

Science. 2015 Apr 3;348(6230):136-9. doi: 10.1126/science.1258867. Epub 2015 Mar 5.

8.

Recognition of tumors by the innate immune system and natural killer cells.

Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH.

Adv Immunol. 2014;122:91-128. doi: 10.1016/B978-0-12-800267-4.00003-1. Review.

9.

Regulation of ligands for the NKG2D activating receptor.

Raulet DH, Gasser S, Gowen BG, Deng W, Jung H.

Annu Rev Immunol. 2013;31:413-41. doi: 10.1146/annurev-immunol-032712-095951. Epub 2013 Jan 3. Review.

Supplemental Content

Loading ...
Support Center